Indoco Remedies
A s per the un-audited results for First Quarter (Q1) of the financial year 2012-13, Indoco Remedies recorded a growth of 20.2 per cent in the revenues at Rs 1511.6 million during Q1 of FY 2012-13 as compared to Rs 1257.4 million over the same quarter last year. The earnings before interest, taxes, depreciation, and amortisation (EBIDTA) for the quarter was 19.3 per cent at Rs 292.2 million as compared to 16.3 per cent at Rs 205.0 million over the same quarter last year.
Jubilant Lifesciences
In Q1 FY2013, income from operations was at all time high of Rs 1,240 crore with 31 per cent year-on-year (YoY) growth. The growth was backed by overall volume increase of 23 per cent. Foreign exchange movement was also favourable in terms of revenue and profit growth. EBITDA at all time high of Rs 277 crore grew 46 per cent YoY and the EBITDA margins were at 22.3 per cent, up from 20 per cent reported last year. Profit before exceptional items, tax and minority interest was at Rs 158 crore, up 64 per cent YoY. Reported Profit after Tax (PAT) of Rs 5 crore was after accounting for unrealised mark to market forex loss on loans of Rs 104 crore. Normalised PAT stood at Rs 109 crore for Q1’FY13, up 34 per cent compared to same quarter in FY12.
Lupin
Lupin’s net sales grew by 44 per cent to Rs 22,192 million during Q1 FY 2012-13, up from Rs 15,432 million (Q1 FY 2011-12). EBITDA grew by 63 per cent to Rs 4,811 million during Q1 FY 2012-13, up from Rs 2,955 million (Q1 FY 2011-12). Profit before tax (PBT) grew by 67 per cent to Rs 4,057 million during Q1 FY 2012-13, up from Rs 2,426 million (Q1 FY 2011-12). Net profits grew by 33 per cent to Rs 2,804 million during Q1 FY 2012-13, up from Rs 2,101 million (Q1 FY 2011-12).
Clariant Chemicals
Clariant Chemicals net sales for the quarter ended June 30, 2012 is up at Rs 282.1 crore from Rs 260.1 crore for the corresponding period of the previous year. The profit (before exceptional items) for the same period stood at Rs 44.1 crore compared to Rs 43.7 crore in the previous year period. After considering the exceptional items and tax expenses, the net profit for the period amounted to Rs 30.8 crore as against Rs 30.4 crore in the previous year period.
For the six month period ending June 30, 2012, the net sales rose from Rs 488.3 crore to Rs 521.4 crore, in comparison with the corresponding period of previous year. The net profit for the period amounted to Rs 62.5 crore as compared to Rs 253.9 crore in the previous year period. The board of directors of the company has considered the payment of an interim dividend of Rs 10 (100 per cent) per share for the year 2012.
Cadila Healthcare
Cadila Helathcare has reported its Q1FY13 results. According to a report compiled by Fortune Group, the total income grew by 25.2 per cent YoY due to 27.7 per cent and 50.1 per cent growth in Indian and US formulations business respectively. EBITDA margin at 22.1 per cent improved by 125bps sequentially and is now consistently improving QoQ. PAT declined by 3.1 per cent YoY due to higher tax rate as its Sikkim partnership firm has now come under MAT post budget.
Glenmark Pharma
According to a report compiled by Fortune Group, Glenmark Pharma’s Q1FY13 numbers exceeded its expectations. The total income grew by 19.8 per cent YoY due to excellent growth across most business segments. Growing by 364bps sequentially, EBITDA margin at 21.1 per cent was above the estimate due to presence of Malarone and Cutivate in the US and strong domestic growth. Adjusted PAT grew slower than EBITDA at 15.5 per cent YoY due to higher tax rate and depreciation. Excluding lincensing income, Glenmark’s speciality business posted 22.9 per cent YoY growth as the company made excellent gains in India and ROW markets. India business continued to do well and posted 24.1 per cent growth YoY. The company’s generics business grew by a staggering 57.7 per cent on account of robust growth across regions.
Wockhardt
Wockhardt has delivered 95 per cent increase in Profit After Tax at Rs 378 crore in Q1 of financial year 2012-13. The EBITDA at Rs 502 crore grew by 61 per cent and represented 10th consecutive quarter of sequential growth. Consolidated revenues grew by 35 per cent to Rs 1,426 crore over the corresponding quarter of financial year 2011-12. This represented 5th consecutive quarter of sequential growth in consolidated revenues. Wockhardt’s US and EU operations have been the major contributor in its growth and the momentum continued in this quarter as they contributed to 71 per cent of consolidated revenues.
Cipla
Fortune Group in its report has mentioned that Cipla’s Q1FY13 numbers were higher than expectation. The total income grew by 23.3 per cent YoY due to higher than expected growth domestically and Lexapro supply under 180 days exclusivity to Teva. The management believes that the growth in FY13 would be higher than 10-15 per cent as was guided after the Q4FY12 results. It has indicated that the growth of domestic anti-asthma and antibiotics space was in excess of 20 per cent. Domestic growth is expected to decline to 16-17 per cent going forward. The SEZ in Indore is currently operating at 45-50 per cent capacity and has generated Rs 1,900 million in sales.
Aurobindo Pharma
According to a report by Fortune Group, Aurobindo Pharma’s Q1FY13 numbers were below estimates. Led by its API and US formulations business, total income grew by 12.8 per cent YoY. The PAT declined by 53.3 per cent YoY due to higher interest costs and depreciation.
